Aeterna Zentaris Inc. (NASDAQ:AEZS) rose 6.8% during trading on Tuesday . The company traded as high as $3.66 and last traded at $3.61, with a volume of 304,897 shares trading hands. The stock had previously closed at $3.38.

AEZS has been the subject of a number of analyst reports. Maxim Group reissued a “buy” rating and issued a $11.00 price target on shares of Aeterna Zentaris in a research report on Tuesday, May 10th. Canaccord Genuity restated a “buy” rating and issued a $9.00 price objective (down previously from $13.00) on shares of Aeterna Zentaris in a research note on Monday, April 4th. Finally, HC Wainwright restated a “buy” rating and issued a $12.00 price objective on shares of Aeterna Zentaris in a research note on Sunday.

The firm has a 50-day moving average of $3.44 and a 200-day moving average of $3.49. The stock’s market capitalization is $35.98 million.

Aeterna Zentaris Inc is a Canada-based specialty biopharmaceutical company engaged in developing treatments in oncology, endocrinology and women’s health. The Company has three wholly owned direct and indirect subsidiaries: AEZS GmbH, based in Frankfurt, Germany, Zentaris IVF GmbH, a direct wholly owned subsidiary of AEZS Germany based in Frankfurt, Germany, and Aeterna Zentaris, Inc Its drug development efforts are focused on two compounds, zoptarelin doxorubicin and Macrilen, which are in clinical development, and on two oncology compounds (an Erk inhibitor and Luteinizing Hormone-Releasing Hormone-disorazol Z product candidates), which are in pre-clinical development.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.